Michael Lahn
Impact in
- Oncology top 2%
- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
Papers in
-
- TGF-β signaling in diseases 20
- Protein Kinase Regulation and GTPase Signaling 3
- Melanoma and MAPK Pathways 3
- Cell death mechanisms and regulation 2
- Oncology 16
- Pancreatic and Hepatic Oncology Research 5
- Colorectal Cancer Treatments and Studies 4
- Co-authors
- Ann Cleverly (17 shared papers)Gianluigi Giannelli (4 shared papers)Ivelina Gueorguieva (11 shared papers)Erica Villa (1 shared paper)Karim A. Benhadji (5 shared papers)Shawn T. Estrem (4 shared papers)Anja J. Stauber (2 shared papers)Stephan Herbertz (1 shared paper)
- Journals
- Journal of Clinical Oncology (5 papers)Investigational New Drugs (4 papers)Annals of Oncology (3 papers)Biomarkers (2 papers)Cancer Research (2 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Michael Lahn
42 papers receiving 2.2k citations
Michael Lahn's Hit Papers
Peers
Comparison fields: 5 of 87
- Oncology 1.0k
- Cancer Research 337
- Hepatology 163
- Molecular Biology 1.2k
- Immunology 349
Countries citing papers authored by Michael Lahn
This map shows the geographic impact of Michael Lahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lahn more than expected).
Fields of papers citing papers by Michael Lahn
This network shows the impact of papers produced by Michael Lahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lahn. The network helps show where Michael Lahn may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Lahn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway Hit paper breakdown → | 2015 | 462 |
| 2 | 2014 | 216 | |
| 3 | 2019 | 203 | |
| 4 | 2014 | 200 | |
| 5 | 2011 | 197 | |
| 6 | 2014 | 94 | |
| 7 | 2014 | 82 | |
| 8 | 2013 | 67 | |
| 9 | 2005 | 62 | |
| 10 | 2008 | 52 | |
| 11 | 2020 | 49 | |
| 12 | 2011 | 43 | |
| 13 | 2004 | 39 | |
| 14 | 2015 | 39 | |
| 15 | 2014 | 37 | |
| 16 | 2021 | 36 | |
| 17 | 2004 | 32 | |
| 18 | 2007 | 30 | |
| 19 | 2014 | 30 | |
| 20 | 2010 | 25 |
About Michael Lahn
Michael Lahn is a scholar working on Molecular Biology, Oncology, Cancer Research, Genetics and Pathology and Forensic Medicine, having authored 42 papers that have together received 2.2k indexed citations. Recurring topics across this work include TGF-β signaling in diseases (20 papers), Cancer, Hypoxia, and Metabolism (7 papers), Pancreatic and Hepatic Oncology Research (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Glioma Diagnosis and Treatment (4 papers), Protein Kinase Regulation and GTPase Signaling (3 papers), Melanoma and MAPK Pathways (3 papers) and Cell death mechanisms and regulation (2 papers). The work is most often cited by research in Oncology (1.0k citations), Cancer Research (337 citations), Hepatology (163 citations), Molecular Biology (1.2k citations) and Immunology (349 citations). Michael Lahn has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Ann Cleverly, Gianluigi Giannelli, Ivelina Gueorguieva, Erica Villa, Karim A. Benhadji, Shawn T. Estrem, Anja J. Stauber, Stephan Herbertz, J. Scott Sawyer and Christopher A. Slapak. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Annals of Oncology, Biomarkers and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.